Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (642)	4/30/1998 12:58:00 AM
From: tom jones	Read Replies (2) \| Respond to of 834

To all: I talked with investor relations 4-29. Novastan was first made by Genentech and was sold to Mitsubishi which sells it in Japan. If Texas Biotechnology ever sells it here they will pay a small royalty to Mitsubishi. The May 15 deadline for Novastan comes from the last day (January 23)data was given to the food and drug people and then add 90 days. So if they keep to the 90 days there will be news before May 15. Novastan for acute myocardial infarction article 3-17-1997. They are waiting for Smithkline Beechum to decide if they should go forward with this one. TBC 11251 for congestive heart failure article 2-11-1998. They are waiting for a partnership ($) before going on to large trials which will be phase IIb. They are doing some small trials right now with about 20 people. So it seems to me Novastan approval is not a sure thing and there may be time to buy TXB after the news if it is good. There may be news about a partnership which will help the stock. Tom